Merck receives FDA approval for RSV medication

Enflonsia, Merck’s medication to treat respiratory syncytial virus (RSV) in infants, has been approved by the FDA. It will now compete with Sanofi and AstraZeneca’s Beyfortus, which was approved by the FDA in July 2023.

In the US, there are roughly 58,000 children under age 5 who are hospitalized annually with RSV infections, with between 100 to 500 deaths per year in the age group. In low- and middle-income nations, RSV is the second-leading cause of death after malaria.

Globally, there are roughly 3 million children younger than age 5 who are hospitalized with the infection each year, and 100,000 who die.

Click here to read the entire article.